The obesity treatment landscape looks nothing like it did three years ago. Four distinct drug classes, multiple new indications, and the first-ever oral GLP-1 receptor agonist have all entered clinical practice since 2023. For physicians managing patients with overweight and obesity, staying current is no longer optional.
So, let’s look at seven FDA-approved agents that are shaping prescribing decisions in 2026, backed by Phase 3 trial data and covering four different mechanisms of action.
1. Wegovy (Semaglutide 2.4 mg): Now Approved for MASH and Cardiovascular Risk Reduction
Wegovy has accumulated one of the broadest label sets of any obesity drug on the market. Beyond chronic weight management, it now carries two additional FDA-approved indications that significantly change how it fits into multimorbid patient care.
The SELECT trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% over a mean follow-up of nearly 40 months.
This was the first GLP-1 cardiovascular outcome trial in a non-diabetic obese population, and it changed the risk-benefit calculus for a large segment of patients.
The Phase 3 ESSENCE trial enrolled 1,197 adults with biopsy-confirmed MASH and moderate-to-advanced liver fibrosis (stage F2 to F3). At the week 72 interim analysis, 62.9% of semaglutide-treated patients achieved resolution of steatohepatitis without worsening fibrosis, compared with 34.3% on placebo.
FDA approval followed in August 2025 under accelerated approval, making Wegovy only the second drug approved for MASH and the only GLP-1 with that indication.
2. Zepbound (Tirzepatide): Dual GLP-1/GIP Agonist for Obesity and Obstructive Sleep Apnea
Tirzepatide is a dual agonist of the GLP-1 and GIP receptors, a mechanistic distinction that appears to translate into greater weight loss than GLP-1 monotherapy alone. The head-to-head SURMOUNT-5 trial confirmed tirzepatide's superiority over semaglutide in weight reduction. The SURMOUNT-1 trial showed a mean weight loss of 20.9% at the 15 mg dose at 72 weeks, in adults with obesity without diabetes.
Zepbound became the first prescription drug approved for moderate-to-severe OSA in adults with obesity. The SURMOUNT-OSA Phase 3 trials enrolled 469 adults across two parallel arms. In patients not using PAP therapy, tirzepatide reduced apnea-hypopnea index events by approximately 25 per hour versus 5 for placebo.
Between 42% and 50% of tirzepatide patients achieved OSA remission or mild non-symptomatic disease at 52 weeks. Patients also lost an average of 18% to 20% of body weight over the trial period.
3. Wegovy Pill (Oral Semaglutide 25 mg): First Oral GLP-1 Receptor Agonist
Injection aversion is a real and documented barrier to GLP-1 therapy uptake. The approval of oral semaglutide 25 mg as the first GLP-1 receptor agonist pill for weight management removes that obstacle for a substantial group of patients.
In the OASIS 4 Phase 3 trial at 64 weeks, patients who remained on treatment achieved a mean weight loss of 16.6% versus 2.7% with placebo. About one-third of adherent patients achieved 20% or greater weight loss, a benchmark previously tied to surgical or high-potency injectable approaches.
The tablet requires administration on an empty stomach with a small amount of water, followed by a 30-minute fast before eating or drinking. The drug also carries the same cardiovascular risk reduction indication as injectable Wegovy.
4. Wegovy HD (Semaglutide 7.2 mg)
Wegovy HD is approved as an add-on step for patients who have already tolerated semaglutide 2.4 mg for at least four weeks but have not achieved sufficient weight loss. At three times the previous maximum dose, the clinical outcomes move into a range historically associated with bariatric surgery.
The Phase 3b STEP UP trial enrolled 1,407 adults with obesity without diabetes over 72 weeks. About 33% of patients on the higher dose achieved 25% or more total body weight loss, compared with 17% on the standard dose.
One new adverse event to counsel patients on: dysesthesia, described as altered skin sensation, tingling, or increased sensitivity, was reported in roughly 22% of patients on 7.2 mg compared with 6% at the standard dose and 0.3% on placebo. Most events were mild and resolved on their own, but the FDA has flagged this pattern for ongoing investigation.
5. Foundayo (Orforglipron)
Orforglipron is not just another oral GLP-1. Unlike semaglutide, which is a peptide molecule requiring specific absorption conditions, orforglipron is a non-peptide small-molecule GLP-1 receptor agonist. So, it can be taken at any time of day, with or without food, without any fasting window.
The Phase 3 ATTAIN-1 trial enrolled adults with obesity or overweight, producing a mean weight loss of 11.2% at the highest dose (36 mg) at 72 weeks. The ATTAIN-2 trial enrolled patients with both obesity and type 2 diabetes, where weight loss reached 9.6% at the highest dose.
The FDA reviewed Foundayo's application in just 50 days under the Commissioner's National Priority Voucher pilot program, the fastest new molecular entity approval since 2002.
6. Imcivree (Setmelanotide): For Acquired Hypothalamic Obesity
Setmelanotide works through a completely different mechanism from everything else on this list. It is a melanocortin-4 receptor (MC4R) agonist that directly restores disrupted hypothalamic signaling. This matters because for patients with acquired hypothalamic obesity (HO), GLP-1 therapies are not effective.
Acquired hypothalamic obesity most often follows treatment of craniopharyngioma or other hypothalamic-pituitary tumors, but can also result from traumatic brain injury, stroke, or inflammation. Patients experience relentless, pathological hyperphagia and progressive, severe weight gain that does not respond to lifestyle interventions.
The Phase 3 TRANSCEND trial enrolled 142 adults and children aged four years and older with acquired HO. At 52 weeks, setmelanotide produced a mean 15.8% BMI reduction. Hunger scores also improved meaningfully in patients aged 12 and older.
Prescribers should monitor for skin hyperpigmentation, depression, and suicidal ideation, which require baseline mood assessment and ongoing follow-up.
7. Generic Phentermine/Topiramate ER
Most patients who could benefit from pharmacotherapy for obesity never access it. Cost is the most commonly cited reason. The June 2024 FDA approval of generic phentermine/topiramate extended-release and its May 2025 market launch changes the cost equation for a significant portion of that group.
The brand version, Qsymia, has been FDA-approved for chronic weight management in adults since 2012 and was expanded to adolescents aged 12 and older in 2022. It combines phentermine, a sympathomimetic anorectic, with topiramate, which independently has seizure and migraine indications. The combination produces synergistic appetite suppression. Phase 3 trial data across the CONQUER and EQUIP trials demonstrated 7% to 9% placebo-adjusted weight loss at maximum dose (15 mg/92 mg) over 56 weeks.
For patients who cannot tolerate injectables, who prefer oral therapy without the dietary restrictions of oral semaglutide, or who are simply priced out of GLP-1 options, generic phentermine/topiramate ER is a legitimate prescribing choice that is now substantially more affordable.
Managing the Long Game
Across all seven of these drugs, the clinical evidence points to the same challenge. Weight loss slows or reverses after discontinuation. Adherence drops without structured follow-up. Dose titration decisions require regular, timely contact between clinician and patient. The pharmacology is increasingly solid. The infrastructure for sustained longitudinal care often is not.
That is the problem FRQtech was built to address. FRQtech deploys conversational AI agents that handle structured patient follow-up on behalf of physicians and obesity medicine practices, including routine weight check-ins, symptom monitoring, medication adherence prompts, and titration reminders. Patients stay connected to their care between appointments. Clinicians receive organized, actionable data without adding to staff workload.
As the obesity pharmacotherapy toolkit expands, the bottleneck increasingly is not the medication. It is the sustained follow-through required to realize each drug's full clinical potential. That is where the next improvement in patient outcomes will come from.